Biologica Technologies  

Visit #4820 to learn about ProteiOS growth factor!

Biologica Technologies is a company fully dedicated to improving patients' lives and the health care providers’ experience through innovative biologic solutions.  Our core, proprietary technology, ProteiOS® growth factor, possesses the largest amount of non-recombinant osteoinductive, angiogenic and mitogenic growth factors on the market today.

Brands: ProteiOS, Growth Factor, Biologic


ProteiOS - NASS 2020

 Press Releases

  • CARLSBAD, Calif.Oct. 6, 2020 /PRNewswire/ -- Biologica Technologies, developers and marketers of ProteiOS®, announced the introduction and initial usage of their growth factor enriched cellular bone matrix (CBM), OsseoGEN. OsseoGEN CBM contains all three elements needed for bone regeneration; osteoconductivity, osteoinductivity and osteogenicity and is supplied via an open-bore syringe for easy dispensing. 

    Following in the footsteps of ProteiOS with its novel, proprietary processing technology, OsseoGEN contains significant osteoinductive, angiogenic and mitogenic growth factors setting it apart from other cellular bone matrices on the market today.  OsseoGEN is DMSO-free, eliminating the need to rinse and decant the tissue prior to implantation, and possesses a thaw time approximately half of competitive CBMs being used today.

    "We are excited to bring this innovative bone graft to the market and demonstrate clinical efficacy in a segment of the market that lacks sufficient clinical proof," stated Amit Govil, president and founder of Biologica Technologies, "We feel that the growth factor enrichment processes that are utilized to produce OsseoGEN will provide surgeons with another option to improve patient outcomes."

    About Biologica Technologies
    Founded in 2015, Biologica Technologies is a company focused on providing clinically relevant biologic solutions across multiple medical specialties. Biologica has developed innovative and ground breaking methods to access the naturally occurring growth factors found within allograft tissue, with ProteiOS growth factor being their first introduction into the orthopaedic and neurosurgery markets. The company is privately-held and headquartered in Carlsbad, CA

    Related Links 

    SOURCE Biologica Technologies

 Featured Products

  • ProteiOS growth factor
    ProteiOS® is the only non-recombinant allogeneic derived growth factor, containing over 600 osteoinductive, angiogenic and mitogenic growth factors...

  • Unlike the various recombinant growth factors on the market today (i.e. rhBMP-2, rhPDGF-BB), ProteiOS is not limited to a single growth factor, possessing an array of osteoinductive, chemotactic, angiogenic and mitogenic growth factors that can be added to a surgeon's scaffold of choice. 



    • Long-term sustained release of growth factors
    • High growth factor binding to a synthetic scaffold when measured at 15 minutes
    • Cost effective solution compared to rhBMP-2 
    • Non-immunogenic response
    • Can be utilized with any scaffold
    • No refrigeration or special storage requirements
    • Terminally sterilized via gamma irradiation

  • OsseoGEN
    Continuing with Biologica's unique ability to increase allogeneic growth factors, OsseoGEN is a cellular bone matrix containing progenitor cells, demineralized bone fibers, and significant osteoinductive, mitogenic and angiogenic growth factors. ​...

  • OsseoGEN is Biologica's cell-based matrix utilizing our proprietary tissue processing method.  OsseoGEN continues Biologica's ability of processing unique products with increased levels of osteoinductive, chemotactic, angiogenic and mitogenic growth factors.

Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".